What Is Cartalax?
Cartalax is a three-amino-acid peptide: alanine, glutamic acid and aspartic acid, written Ala-Glu-Asp or AED. Some of the research literature refers to it by the code T-31.[8] It comes out of the "peptide bioregulator" program led by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, which proposes that very short peptides can enter cells and switch tissue-specific genes on or off.[1] Cartalax is the member of that family aimed at cartilage.
That is the theory. What actually exists is a set of cell-culture experiments, a handful of rat studies, and no published human trials. Most of the work comes from Khavinson's own group and its collaborators, and it has not been independently replicated.
If you found Cartalax through a vendor page promising joint repair, the short version is this: the lab findings are coherent and point in an interesting direction, but nobody has shown that injecting or swallowing AED does anything for a human knee.
- Cartalax is the synthetic tripeptide Ala-Glu-Asp (AED), developed by Khavinson's group in Russia as a cartilage "bioregulator."
- Its evidence base is cell-culture and rat research: AED reduced aging and inflammation markers in chondrocytes and increased cartilage-building proteins in aging stem cells.
- No human trial of Cartalax appears in PubMed or on ClinicalTrials.gov (searched October 2026).
- It is not FDA-approved for any use and is sold as a "research use only" vial or as an oral supplement.
- There is no established human dose. Online protocols vary roughly 50-fold, from about 200 µg to 10 mg a day.
| Common Name | Cartalax |
| Sequence | Ala-Glu-Asp (AED); coded T-31 in some studies |
| Formula / Molecular Weight | C12H19N3O8 / about 333 Da |
| Class | Synthetic short peptide ("peptide bioregulator") |
| Developed by | Khavinson group, St. Petersburg Institute of Bioregulation and Gerontology |
| Primary Research Areas | Cartilage cell aging, stem cell differentiation, skin fibroblast aging, kidney cell cultures |
| Human Trials | None found in PubMed or ClinicalTrials.gov |
| FDA Status | Not approved for any indication |
| Forms Sold | 20–25 mg lyophilized "research" vials; oral capsules marketed as supplements |
| Typical Dose | No established human dose |
How Does Cartalax Work?
The proposed mechanism is unusual, so it helps to separate what was measured from what is inferred.
Khavinson's group argues that peptides of two to seven amino acids are small enough to cross cell and nuclear membranes and bind DNA or histone proteins directly, changing which genes are read.[1] In a 2014 study on aging kidney cells, the group modeled how AED might sit in the minor groove of DNA, and reported that AED raised SIRT6 (a protein linked to DNA repair and cell longevity) while lowering the aging markers p16, p21 and p53.[2] The DNA-binding part comes from computer modeling, not from a direct measurement in the cells.
For cartilage specifically, the measured effects are these:
- Aging chondrocytes. Old cartilage cells develop a "senescence-associated secretory phenotype," pumping out inflammatory signals that damage surrounding tissue. AED lowered the pro-aging proteins p16, p21 and p53 and the inflammatory cytokines TNF-α and IL-1α in these cells, and normalized levels of the longevity-linked protein Sirt1, which falls as the cells age.[3]
- Stem cells turning into cartilage. In human mesenchymal stem cells aged in culture, AED at 200 ng/mL increased gene expression and protein production of SOX9, aggrecan, type II collagen and COMP, the core building blocks of cartilage.[4]
The same pattern of "less aging signal, more structural protein" shows up in other cell types. In aging human skin fibroblasts, AED increased sirtuin-1, sirtuin-6 and type I collagen,[5] and in an earlier study it reduced the enzyme MMP-9, which breaks down the tissue matrix, and suppressed cell death.[6] In aging stem cell cultures, AED and two related peptides raised expression of the growth factor gene IGF1 by roughly 3.5- to 5.6-fold.[7]
Why the 'bioregulator' label matters
Khavinson's model claims each short peptide is tissue-specific: AED for cartilage, other sequences for the pineal gland, thymus, blood vessels and so on. The cell studies do show AED acting on cartilage cells, but they also show it acting on skin, kidney and stem cells. The tissue-specificity idea is a hypothesis from the developers, not an established property of the molecule.
What the Clinical Evidence Actually Shows
There is no clinical evidence in the usual sense, because no human trial of Cartalax has been published in an indexed journal or registered on ClinicalTrials.gov. What exists falls into three groups.
Cell-culture studies. These are the bulk of the evidence and are described above: chondrocytes,[3] stem cells,[4][7] skin fibroblasts[5][6] and kidney cells.[2][8] They are consistent with each other, which counts for something. They are also almost entirely from one research network, often published in the Russian-language journal Advances in Gerontology, and they test AED at controlled concentrations on isolated cells. That is a long way from a peptide injected under the skin and having to reach cartilage, which has almost no blood supply.
Animal studies. In rats with surgically induced osteoporosis, T-31 (AED) prevented the loss of bone mineral density and partly reversed it. In the same study, a cartilage tissue extract worked noticeably better than the synthetic peptide.[10] In rats with drug-induced kidney failure, AED reduced protein loss in urine, though two related peptides had broader protective effects.[9] In organ cultures from young and old rats, AED increased kidney cell renewal, again less strongly than a kidney tissue extract.[8]
Results that did not go AED's way. These get left out of most vendor pages. In aging thymus cells, AED (as T-31) showed no anti-aging effect at all; only a different peptide did.[11] And in a stem cell study on nerve cell development, AED on its own was not among the peptides that raised the neuronal markers measured.[12]
You may also see claims of Russian human studies reporting large improvements in osteoarthritis pain and mobility. We could not find any such study in PubMed. If a seller cites one, ask for the journal reference.
What the Evidence Does Not Show
- Cartilage repair in people. No study has measured cartilage thickness, joint space, pain or function in humans taking Cartalax.
- That injected AED reaches the joint. None of the published work tracks where the peptide goes after injection or swallowing, or how long it lasts.
- A working dose. Cell studies used about 200 ng/mL in a dish.[4] There is no animal-to-human dose conversion study and no human dose-finding trial.
- Benefit over existing options. Nothing compares Cartalax with physical therapy, weight loss, injections or any other osteoarthritis treatment.
- Safety. No human safety data exists, short- or long-term.
- Independent confirmation. We found no lab outside Khavinson's network reproducing the core cartilage findings.
Typical Dosing — What the Research Has Used
No established human dose
No published trial has established a safe or effective human dose of Cartalax. Everything below describes what is sold and what circulates online, not dosing guidance.
The only concentrations in the research are cell-culture doses, around 200 ng/mL of AED added to stem cells in a dish.[4] That figure does not translate to a human dose in any meaningful way.
Outside the research, two very different products are sold under the Cartalax name:
- Oral capsules. Marketed as a dietary supplement, typically labeled at 0.1 mg of peptide per capsule.
- Injectable vials. 20–25 mg of lyophilized peptide sold "for research use only." The daily amounts quoted online range from about 200 µg to 10 mg, roughly a 50-fold spread. A commonly discussed community schedule starts at 2 mg once daily and rises to 5 mg over 12 weeks; like the others, it does not come from a trial.
A range that wide is itself informative: it means nobody has done the work to find out what dose, if any, does something in a person. Our Cartalax dosing protocol page covers that community schedule and the reconstitution math for the 20 mg vial, which is useful for measuring accurately but is not evidence that the dose works.
Side Effects — What to Actually Expect
There is no human safety data on Cartalax, so there is no evidence-based side effect profile. Nobody can tell you what the common side effects are, because no one has collected them in a study.
What can reasonably be said:
- Injection-related risks apply to any injected research peptide: redness, pain or swelling at the site, and infection if the product or technique isn't sterile.
- Product quality is the bigger unknown. "Research use only" vials are not made under drug manufacturing rules. Purity, actual peptide content and sterility depend entirely on the seller.
- Unknown long-term effects. The proposed mechanism involves changing gene expression. Even if that turns out to be modest, there is no data on what repeated courses do over years.
If you have a joint condition, an autoimmune disease, kidney disease, or are pregnant or breastfeeding, the absence of any safety data is a strong reason to talk to a physician before using it.
Regulatory & Access Status
Access status as of October 2026
Cartalax is not FDA-approved for any indication. It is not an approved drug, so it cannot be prescribed as one. Only three of the clinics in the MyPeptideMatch directory list Cartalax among the peptides they offer, compared with hundreds for BPC-157.
In the US, Cartalax is available in two ways, neither of which involves FDA review of safety or effectiveness. Injectable vials are sold by research chemical vendors labeled "not for human consumption," and oral capsules are sold as dietary supplements, which the FDA does not approve before sale. Selling a research peptide for human use is a regulatory problem for the seller, and buying one means accepting that nobody has verified what is in the vial.
Sourcing & Safety
If you decide to buy Cartalax anyway, these checks matter more than the brand name:
- An independent certificate of analysis (COA) from a named third-party lab, dated, for the specific batch you receive.
- HPLC purity of at least 98%, plus mass spectrometry confirming the compound is actually Ala-Glu-Asp. Some vendor and reference pages list the wrong sequence for Cartalax, so check the COA's sequence and molecular weight (about 333 Da).
- Sterility and endotoxin testing for anything you plan to inject.
Treat as red flags: no third-party COA, claims that Cartalax "regenerates cartilage" or treats arthritis, prices far below other vendors, and references to human studies that can't be found in PubMed.
What Makes Cartalax Different
Most peptides discussed for joints, like BPC-157 and TB-500, are pitched as tissue-healing signals that act after an injury. Cartalax is pitched differently: as a slow "regulator" that nudges aging cartilage cells back toward a younger pattern of gene activity, taken in short courses months apart. It is also far shorter, at three amino acids against fifteen for BPC-157 and seven for TB-500.
Cartalax vs. Other Peptides Discussed for Joints
| Parameter | Cartalax | BPC-157 | TB-500 |
|---|---|---|---|
| Length | 3 amino acids (Ala-Glu-Asp) | 15 amino acids | 7 amino acids (thymosin beta-4 fragment) |
| Proposed role | Gene regulation in aging cartilage cells | Tissue repair and blood vessel growth | Cell migration and tissue repair |
| Main evidence | Cell cultures, a few rat studies | Mostly rodent studies | Mostly animal studies |
| Published human trials | None | Very limited | None for TB-500 itself |
| FDA status | Not approved | Not approved | Not approved |
| Tested in combination | No | No combination trials with Cartalax | No combination trials with Cartalax |
FAQ
What is Cartalax?
Cartalax is a synthetic tripeptide, alanine-glutamic acid-aspartic acid (Ala-Glu-Asp, or AED), developed by Vladimir Khavinson's group in St. Petersburg as a 'peptide bioregulator' for cartilage. It is sold as a research peptide and as an oral supplement, but it is not an approved drug anywhere in the US.
What is Cartalax used for?
It is marketed for joint and cartilage health, mainly osteoarthritis and age-related joint wear. The research behind that claim is cell-culture work on aging chondrocytes and stem cells, plus one rat study on bone density. No human trial of Cartalax has been published in PubMed or registered on ClinicalTrials.gov.
What are the benefits of Cartalax?
In lab studies, AED reduced markers of cell aging and inflammation in chondrocytes, increased cartilage-building proteins (SOX9, aggrecan, type II collagen) in aging stem cells, and raised collagen I and sirtuin levels in skin cells. Whether any of that happens in a human joint is unknown.
Is Cartalax FDA approved?
No. Cartalax has no FDA approval for any use. Injectable vials are sold labeled 'for research use only', which means they are not made or tested to drug standards for human use.
What dose of Cartalax is used?
No human dose has been established by any published trial. Cell studies used concentrations around 200 ng/mL, which do not convert to a human dose. Community-reported amounts for the injectable vials range from about 200 µg to 10 mg a day, with 2–5 mg once daily commonly discussed. That spread reflects the absence of dose-finding research.
Can Cartalax be stacked with BPC-157 or TB-500?
People do combine them, but no study has tested Cartalax together with BPC-157 or TB-500. Any claim of synergy between them is speculation, not research.
Is Cartalax a Khavinson peptide?
Yes. It comes from Vladimir Khavinson's peptide bioregulator research in St. Petersburg, the same program behind Epithalon (Ala-Glu-Asp-Gly), which differs from Cartalax by a single added amino acid.
Is Cartalax the same as AED peptide or T-31?
Yes. AED is the one-letter code for Ala-Glu-Asp, and T-31 is the code used in some of the group's earlier papers.[8]
Does Cartalax work for arthritis?
Nobody knows. The cell studies are relevant to osteoarthritis biology, but no study has tested Cartalax in people with arthritis.
How is Cartalax different from Bronchogen?
Bronchogen is Ala-Glu-Asp-Leu, a four-amino-acid peptide from the same program that the developers associate with lung tissue.[13] The two are sometimes confused online because their sequences overlap.
Related Peptides & Comparisons
If you are looking at Cartalax for joint pain, BPC-157 and TB-500 are the peptides most often discussed alongside it, and both have deeper (though still mostly animal) research behind them. For the broader set of options, see our guide to peptides for tissue repair and recovery. From the same bioregulator family, Pinealon and Vilon are the most searched.
References
- Khavinson VK, Popovich IG, Linkova NS, et al. "Peptide Regulation of Gene Expression: A Systematic Review." Molecules. 2021;26(22):7053. PMID: 34834147
- Khavinson VKh, Tarnovskaia SI, Lin'kova NS, et al. "Tripeptides slow down aging process in renal cell culture." Adv Gerontol. 2014;27(4):651-656. PMID: 25946838
- Myakisheva SN, Linkova NS, Kozhevnikova EO, et al. "Peptides prevent the forming of secretory phenotype of chondrocytes associated with the aging." Adv Gerontol. 2023;36(2):234-238. PMID: 37356100
- Myakisheva SN, Linkova NS, Diatlova AS, et al. "The influence of peptides on the chondrogenic differentiation of human mesenchymal stem cells during replicative aging." Adv Gerontol. 2023;36(3):383-390. PMID: 37782646
- Fridman NV, Linkova NS, Kozhevnikova EO, et al. "Comparison of the Effects of KE and AED Peptides on Functional Activity of Human Skin Fibroblasts during Their Replicative Aging." Bull Exp Biol Med. 2020;170(1):154-157. PMID: 33231794
- Lin'kova NS, Drobintseva AO, Orlova OA, et al. "Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro." Bull Exp Biol Med. 2016;161(1):175-178. PMID: 27259496
- Ashapkin V, Khavinson V, Shilovsky G, et al. "Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides." Mol Biol Rep. 2020;47(6):4323-4329. PMID: 32399807
- Chalisova NI, Lin'kova NS, Nichik TE, et al. "Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals." Bull Exp Biol Med. 2015;159(1):124-127. PMID: 26033601
- Zamorskii II, Shchudrova TS, Lin'kova NS, et al. "Peptides Restore Functional State of the Kidneys During Cisplatin-Induced Acute Renal Failure." Bull Exp Biol Med. 2015;159(6):736-739. PMID: 26515176
- Povorozniuk VV, Khavinson VKh, Makogonchuk AV, et al. "Effect of peptide regulators on the structural and functional status of bone tissue in ageing rats." Adv Gerontol. 2007;20(2):134-137. PMID: 18306703
- Lin'kova NS, Polyakova VO, Trofimov AV, et al. "Peptidergic regulation of thymocyte differentiation, proliferation, and apoptosis during aging of the thymus." Bull Exp Biol Med. 2011;151(2):239-242. PMID: 22238759
- Caputi S, Trubiani O, Sinjari B, et al. "Effect of short peptides on neuronal differentiation of stem cells." Int J Immunopathol Pharmacol. 2019;33:2058738419828613. PMID: 30791821
- Khavinson V, Linkova N, Diatlova A, et al. "Peptide Regulation of Cell Differentiation." Stem Cell Rev Rep. 2020;16(1):118-125. PMID: 31808038
This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any treatment.




